TIDMONC
RNS Number : 8535B
Oncimmune Holdings PLC
13 October 2020
13 October 2020
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Agreement with Cedars-Sinai to Profile Immune Response to
COVID-19
Oncimmune Holdings plc (AIM: ONC.L), the leading global
immunodiagnostics group, today announces that, following its
announcement on 6 October that Oncimmune is being funded by the UK
Government to develop a COVID-19 biomarker panel, the Company has
signed a commercial agreement with Cedars-Sinai, California, USA,
to provide antibody profiling in COVID-19 samples as biomarkers for
this disease. Cedars-Sinai is a world-leading medical research
organisation serving more than 1 million people each year in over
40 locations, with more than 4,500 physicians and nurses and 1,500
research projects in progress.
Under this agreement, Cedars-Sinai will provide Oncimmune with
serum samples from staff exposed to or infected with the SARS-CoV-2
virus. The project will identify biomarkers of the COVID-19 disease
and compare these to a control set of healthy patient samples to be
provided by Oncimmune. The project will seek to initially profile
the antibodies of staff working at Cedars-Sinai hospitals to better
understand the effects of the disease in healthcare workers.
On 6 October 2020, we announced Oncimmune's participation in the
IMmunity Profiling of pAtients with COVID-19 for Therapy and Triage
("IMPACTT") programme to develop and validate an Infectious Disease
NavigAID(TM) panel designed to predict COVID-19 disease severity
and therapeutic response. This collaboration with Cedars-Sinai is
the first commercial project to result from this IMPACTT
programme.
Cedars-Sinai will also contribute novel antigens to the COVID-19
panel, and in return, will be the first academic partner to benefit
from this IMPACTT programme. Oncimmune intends to continue to
contract commercially with biopharmaceutical companies and academic
organisations for the use of the COVID-19 panel to gain a deeper
understanding of the immune response to the SARS-CoV-2 virus.
Adam M Hill, CEO of Oncimmune said: "We are delighted to be
partnering with such a prestigious organisation as Cedars-Sinai on
this important programme. Oncimmune is responding to the global
call for innovations to support the fight against COVID-19 by
leveraging our capabilities in immune profiling. In so doing we
will build on our knowledge of the disease and support the
development of vaccines and therapeutics. We expect to announce
further development collaborations and contracts over the coming
months to be followed by contracts with biopharmaceutical companies
once the COVID-19 panel is fully validated."
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, Victoria Ayton
+44 (0)20 3829 5000
N+1 Singer (Joint Broker)
Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Chris Lee
+44 (0)203 705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000
About Oncimmune
Our intimate understanding of the human immune system enables us
to harness its sophisticated response to disease to detect cancer
earlier and to support the development of better therapies.
The key to improving cancer survival is early detection and
better selection for therapy. As a company, we are driven by our
passion to improve cancer survival and give people extra time.
Oncimmune's immunodiagnostic test, EarlyCDT(R) , can detect and
help identify cancer on average four years earlier than standard
clinical diagnosis.
The unique combination of our core technology and understanding
of the immune system, powers our ImmunoINSIGHTS service; a
proprietary platform that enables life science organisations to
optimise drug development and delivery, leading to more effective,
targeted as well as safer treatments for patients.
Oncimmune was founded in 2002 and launched its platform
diagnostic technology in 2009, followed by the launch of its first
commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over
200,000 tests have been performed for patients worldwide. EarlyCDT
Lung was also used in what is believed to be the largest randomised
controlled trial for the early detection of lung cancer using
biomarkers, the successful National Health Service (NHS) Early
detection of Cancer of the Lung ("ECLS") trial of 12,208 high-risk
smokers in Scotland. This trial demonstrated that EarlyCDT Lung
reduced the incidence of patients with late-stage lung cancer or
unclassified presentation at diagnosis, compared to standard
clinical practice.
Oncimmune, headquartered at its laboratory facility in
Nottingham, UK, has a discovery research centre in Dortmund,
Germany and a partner representative office in Shanghai, China.
Oncimmune joined the AIM Market of the London Stock Exchange in May
2016 under the ticker ONC.L
About Cedars-Sinai
Cedars-Sinai is a non-profit academic healthcare organization
serving the diverse Los Angeles community and beyond. With
pioneering medical research achievements, education programs
defining the future of healthcare, and wide-ranging community
benefit activities, Cedars-Sinai is setting new standards for
quality and innovation in patient care. Founded in 1902 as a 12-bed
hospital in the Angelino Heights neighborhood of Los Angeles, today
Cedars-Sinai serves more than 1 million people each year in over 40
locations, with more than 4,500 physicians and nurses and 1,500
research projects in motion.
What is ImmunoINSIGHTS?
The ImmunoINSIGHTS service business leverages Oncimmune's
technology platform and methodologies across multiple diseases, to
offer life-science organisations actionable insights for therapies
across the development and product lifecycle. Our core
immune-profiling technology is underpinned by our library of over
eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into
clinically relevant subgroups, enabling development of targeted and
more effective treatments.
What is SeroTag (TM) ?
Oncimmune's proprietary biomarker discovery engine, which is
leveraged in our ImmunoINSIGHTS services to discover and validate
novel biomarkers can help stratify patients in multiple cancer
indications and with different autoimmune diseases.
This high-throughput, multiplex technology is based on one of
the largest, in-house protein libraries, as well as a unique,
ever-growing repository of disease data for indications including,
but not limited to, autoimmune diseases and cancer. As a result,
SeroTag is helping to address and monitor a number of challenges
currently hindering the successful development and broader
application of both cancer immunotherapies and treatments for
autoimmune diseases.
The platform is being applied to discover and validate
biomarkers and develop precision diagnostic tools from minimally
invasive liquid biopsies. SeroTag analyses autoantibodies-some of
the most stable analytes-and is used most frequently for the
identification of IgG isoforms, in addition to IgM and IgA, from
just a few drops of serum.
The SeroTag platform acts as the primary discovery engine that
feeds into the creation of Oncimmune's NavigAID disease-specific
stratification panels-precision medicine tools which are enabling
patient and disease stratification and support therapeutic
development.
What is NavigAID(TM)?
Oncimmune's NavigAID arrays are thoroughly validated containing
well defined antigen panels, largely encompassing markers of
interest for each of the disease types being investigated.
Our portfolio of panels includes out-of-the-box NavigAID arrays
for immuno-oncology and autoimmune diseases. These validated panels
are frequently used as the starting point for collaborations with
partners to add further markers of interest to their specific
therapy and its specific indication.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRDZMMGGZGGGZZ
(END) Dow Jones Newswires
October 13, 2020 02:00 ET (06:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024